Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense oligonucleotides: a new therapeutic approach

J Temsamani1, P Guinot

  • 1Hybridon Europe, Paris, France.

Biotechnology and Applied Biochemistry
|November 14, 1997
PubMed
Summary

Antisense oligonucleotides offer a new approach to genetic pharmacology, targeting gene expression. While challenges exist, advancements in oligonucleotide design are improving therapeutic safety and efficacy for various diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Target engagement and intracellular delivery of mono- and bivalent LDL receptor-binding peptide-cargo conjugates: Implications for the rational design of new targeted drug therapies.

Journal of controlled release : official journal of the Controlled Release Society·2019
Same author

Detection of hazardous weight-loss substances in adulterated slimming formulations using ultra-high-pressure liquid chromatography with diode-array detection.

Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment·2011
Same author

Comparative pharmacokinetics of antisense oligonucleotides.

Methods in molecular medicine·2011
Same author

Antisense approach for the treatment of cytomegalovirus infection.

Expert opinion on investigational drugs·2005
Same author

Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties.

Journal of neurochemistry·2005
Same author

Vector-mediated drug delivery to the brain.

Expert opinion on biological therapy·2001

Area of Science:

  • Pharmacology
  • Genetics
  • Molecular Biology

Background:

  • Antisense oligonucleotides represent a novel therapeutic modality in genetic pharmacology.
  • These molecules offer high affinity and selectivity for nucleic acid targets.
  • Early development faced challenges requiring significant research and innovation.

Purpose of the Study:

  • To review the development and application of antisense oligonucleotides in therapy.
  • To highlight the transition from first-generation to second-generation oligonucleotide designs.
  • To discuss the potential of antisense technology in treating diseases.

Main Methods:

  • Review of preclinical animal studies demonstrating gene expression inhibition.
  • Analysis of clinical trial data for antisense oligonucleotide therapies.
  • Evaluation of oligonucleotide design principles and their impact on safety and efficacy.

Main Results:

  • First-generation phosphorothioate oligonucleotides showed promise in inhibiting disease-associated protein expression in animal models.
  • Clinical trials provided crucial insights into the practical application and challenges of antisense therapy.
  • Second-generation oligonucleotides have been developed with enhanced safety profiles and improved efficacy.

Conclusions:

  • Antisense oligonucleotide therapy is a rapidly evolving field with significant therapeutic potential.
  • Overcoming initial developmental hurdles has paved the way for more effective oligonucleotide-based treatments.
  • Continued research and clinical evaluation are essential for optimizing antisense oligonucleotide therapies for diverse diseases.

Related Experiment Videos